studies

lung cancer : non small cell (NSCLC), ... vs. pemetrexed plus platin, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsLUX-LUNG 3, 2013 1.12 [0.73; 1.72] 1.12[0.73; 1.72]LUX-LUNG 3, 201310%345NAnot evaluable progression or deaths (PFS)detailed resultsLUX-LUNG 3, 2013 0.47 [0.34; 0.65] 0.47[0.34; 0.65]LUX-LUNG 3, 201310%345NAnot evaluable objective responses (ORR)detailed resultsLUX-LUNG 3, 2013 4.37 [2.63; 7.27] 4.37[2.63; 7.27]LUX-LUNG 3, 201310%345NAnot evaluable TRAE (grade 3-4)detailed resultsLUX-LUNG 3, 2013 0.98 [0.62; 1.54] 0.98[0.62; 1.54]LUX-LUNG 3, 201310%340NAnot evaluable TRAE leading to death (grade 5)detailed resultsLUX-LUNG 3, 2013 3.93 [0.21; 74.98] 3.93[0.21; 74.98]LUX-LUNG 3, 201310%340NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsLUX-LUNG 3, 2013 0.74 [0.36; 1.50] 0.74[0.36; 1.50]LUX-LUNG 3, 201310%340NAnot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-10-03 03:45 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334 - treatments: 472